Home
overview

SAE Media Group’s 6th Annual Conference
3D Cell Culture
February 08-09, 2023
-------------------------------------------------------------------------
Join us in February 2023, as SAE Media Group’s 6th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of clinical applications, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry.

 

3D Cell Culture has gained increasing momentum in the pharmaceutical industry over recent years, with the global 3D Cell Culture market predicted to reach a value of $3.48 Billion by 2028. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. 3D Cell Culture technology promises to offer increased translatability in models and reduce the costly rates of drug attrition in the discovery process -- heralding the next major advance in the discovery of pharmaceuticals.


Rising demand for tissue engineering for the personalised, precision medicine is another key driver of this research -- new technologies in the form of organ-on-chip, microphysiological systems and patient-derived tissues are all burgeoning areas of the field.

 

  • DISCUSS the uses of advanced cell technologies for human tissue bioengineering
  • EXPLORE the regulatory sciences surrounding microphysiological systems, and their development and adoption for drug safety assessment
  • UNCOVER the major benefits of 3D modelling in enhancing clinical translation and predictability
  • UTILISE 3D cell culture for personalised drug screening and high-throughput screening over traditional 2D methods
  • DELVE into advanced case studies looking into organ models: from the blood-brain barrier to liver spheroids
     

AbbVie Pharmaceuticals; Alcyomics ; AstraZeneca; Biocasting; Celink Bioprinting AB; Celvivo; Durham University; Ecole Normale Supérieure Paris-Saclay; Engitix Therapeutics; F. Hoffmann-La Roche Ltd. ; GlaxoSmithKline; Hamilton Bonaduz AG; HUB Organoids; Hubrecht Organoid Technology; Incyte;Janssen (Johnson & Johnson); Merck Healthcare KGaA; NC3Rs; Newcastle University; Newcells Biotech Limited; Novartis Institutes for BioMedical Research; Optics11 B.V.; Philip Morris International; Philip Morris Products S.A.; Promega UK Ltd; REGEMAT 3D; Roche; Sanofi Genzyme; Scripps Research; The Princess Maxima Center of Pediatric Oncology; The University Of Manchester; University Of Geneva; University of Greifswald – Medical Centre; US Food and Drug Administration;

Conference programme

8:00 Registration & Coffee

9:00 Chairs' Opening Remarks

Rhiannon David

Rhiannon David, Director, Microphysiological Systems, AstraZeneca
View Bio

Philip Hewitt

Philip Hewitt, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA

9:10 Innovative Tissue Bioengineering Technologies for In-Vitro Modelling, Screening and Discovery

Stefan Przyborski

Stefan Przyborski, Professor, Durham University
View Bio

  • Optimised cell culture techniques to enhance in vivo physiological comparisons
  • Maximising use of highly specialised tissue models for pre-clinical drug screening and precision medicine 
  • Modelling pathophysiological effects on human tissues
  • New innovations and developments to further enhance bioengineered tissues
  • 9:50 Donor-to-donor variability in human gut adult stem cell (ASC) organoids

    Linda Lieberman

    Linda Lieberman, Head of Host Pathogen Discovery Research, Merck & Co
    View Bio

  • Understanding and overcoming issues with the use of primary tissue culture 
  • Validating human primary tissue culture monitoring
  • Case study data from human gust ASC organoids
  • High-Throughput Screening, therapeutic discovery, and precision medicine: The future of personalised organoids
  • 10:30 Morning Coffee

    11:00 Building a Bridge between 2D iPSC Cardiomyocyte Assays and Engineered Cardiac Tissue – Case Study: Impact of Activin A

    Scott MacDonnell

    Scott MacDonnell, Director New Target Interrogation Group, Regeneron Pharmaceuticals
    View Bio

  • Activin A has been linked to the development of cardiac dysfunction in aging and disease. The underlying mechanism by which Activin A-mediated signaling modifies human cardiomyocyte functions are currently lacking.
  • Using an activin A overexpression animal model, two-dimensional human iPSC-cardiomyocytes, and three-dimensional Human engineered cardiac tissues, we investigated whether activin A signaling impacts cardiomyocyte excitation–contraction coupling mechanisms required to maintain heart function.
     
  • 11:40 Session Reserved for CelVivo

    12:20 Networking Lunch

    13:20 Use of human tissue-specific extracellular matrix hydrogels in

    Luca Frenguelli

    Luca Frenguelli, Director of Biomaterials, Engitix Therapeutics

  •  Advantages of using human tissue specific ECM to recapitulate the pathophysiology of human diseases
  • Established quality control process to enhance reproducibility of 3D cell cultures models
  • Development of in-vitro 3D assays to validate novel targets and screening drugs for the treatment of fibrosis and cancer diseases
  • 14:00 Strengthening the use of 3D Cell Culture models by defining appropriate context for use.

  • Where are we now: 3D Cell Culture Vs Animal Models
  • Comparing uses alternative modelling techniques from tissue bioengineering to organ-on-a-chip 
  • Optimising drug screening with considerations from previous successes
  • Looking to future how combined technologies can impact drug development
     
  • Stefan Przyborski

    Stefan Przyborski, Professor, Durham University
    View Bio

    Etienne De Braekeleer

    Etienne De Braekeleer, Senior Research Scientist, Astrazeneca

    Masato Ohbuchi

    Masato Ohbuchi, Senior Researcher, Astellas Pharma Inc.
    View Bio

    14:40 3D Cell Culturing Technology for Precision Medicine

    Elad Katz

    Elad Katz, Lead, Navigate Precision Biology, University of Dundee
    View Bio

  • Overcoming challenges of limited cell numbers when using patient-derived cells
  • Developing technology for tumour modelling
  • Scalability- collaborating with industry to go from lab bench to clinic
  • 15:20 Afternoon Tea

    15:50 Establishing novel prostate cancer models and assays for drug discovery

    Lewis Chaytor

    Lewis Chaytor, Senior Scientist, Astrazeneca
    View Bio

  • Establishing PDX derived organoids
  • Characterisation of PDX derived organoid models
  • Developing novel assays for cancer organoids
  • Overcoming the challenges of in-vitro cancer modelling.
  • 16:30 Optimising disease modelling with gastrointestinal organoids

    Jessica Klein

    Jessica Klein, Scientist, Contractor, Genentech
    View Bio

  • Development of infection models with organoids and 3D cell culture techniques
  • Controlling organoid polarity to maximise comparison to in vivo conditions
  • Validating and standardising systems for commercial use
  • Looking forward for modelling of the gastrointestinal tract with organoids
  • 17:10 Chairs' Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairs' Opening Remarks

    Rhiannon David

    Rhiannon David, Director, Microphysiological Systems, AstraZeneca
    View Bio

    Philip Hewitt

    Philip Hewitt, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA

    9:10 Improving Pre-Clinical safety assessment with Microphysiological systems

    Rhiannon David

    Rhiannon David, Director, Microphysiological Systems, AstraZeneca
    View Bio

  • Outline the context of use of microphysiological systems (MPS) to generate safety and efficacy data for drug development with improved clinical relevance over more traditional 2D cell culture and animal models.
  • Highlight examples of data generated from these systems that demonstrate the utility of MPS for safety assessment.
  • Current challenges to the adoption and/or development of MPS in the pharmaceutical industry.
  • 9:50 Modelling of acute kidney injury using human renal proximal tubule-on-a-Chip

    Masato Ohbuchi

    Masato Ohbuchi, Senior Researcher, Astellas Pharma Inc.
    View Bio

  • Development of human renal proximal tubule /blood vessel-on-a-chip
  • Disease modelling of acute kidney injury through ischemia and reperfusion
  • Evaluation of protective effect of drugs
  • Prospects for disease modelling in drug discovery research
     
  • 10:30 Morning Coffee

    11:00 Complex human in vitro models in therapeutic antibody pharmacology applications

    Manjunath Hedge

    Manjunath Hedge, Scientific Investigator & Associate Fellow, GlaxoSmithKline

  •  The case for applying physiologically-relevant human in vitro models in the discovery of biologics is unclear, unlike small molecule-based therapeutics.
  •  Novel therapeutic antibody formats, including ADCs, bifunctional or bispecific antibodies, will require better in vitro models to assess their functionality and safety.
  •  Immune-competent models must be generated within human organoid or microphysiological systems to better replicate antibody mode of action and pharmacology and reduce animal use in preclinical studies.
  • Case study: application of Emulate’s primary human co-culture-on-chip model to assess the parameters that affect the in vitro assessment of FcgRIIb-mediated clearance of therapeutic antibodies.
  • 11:40 Benchmarking in vitro blood-brain barrier models to develop the next generation of brain-targeting therapeutics

    Martina Pigoni

    Martina Pigoni, Scientist, Roche Innovation Center

  • Why do we need robust & standardized in vitro BBB models for drug development?
  • Challenges with current BBB models and approaches to address them
  • New developments and future applications of advanced BBB models
  • 12:20 Networking Lunch

    13:20 The importance of using Microphysiological Systems for testing CAR-T efficacy

    Pelin Candarlioglu

    Pelin Candarlioglu, Bioengineer/Cell Biologist, GlaxoSmithKline

    • Strengthening translatability of preclinical testing
    • Benefit of parametric in vitro modelling of cell therapies before FTIH
    • Understanding the impact of MPS in the cell therapy field
     

    14:00 MPS for ADME Applications: Moving from Aspiration to Exploration

    Stephen Fowler

    Stephen Fowler, Clinical Pharmacologist, Roche Pharmaceuticals
    View Bio

  •  How and why are MPS requirements for ADME applications are different to those of in vitro pharmacology or toxicology?
  •  What recent ADME studies have we conducted using Liver Chip and Gut-Liver Chip systems to show opportunities for MPS use?
  •  Why is Modelling and simulation is an essential component to experiment planning and data evaluation?
  • 14:40 Integrated human intestine–liver-on-a-chip for mechanistic toxicity investigations

    Ilona Wehl

    Ilona Wehl, PostDoc, Boehringer Ingelheim Pharma GmbH & Co. KG
    View Bio

  • Microfluidic chip-based co-culture to mimic long-term repeated oral and systemic substance exposure
  • Investigation of GPR40 agonist induced idiosyncratic drug-induced liver injury – a case study
  • Complex cell analysis, including high-content imaging and next-generation sequencing, to elucidate mechanisms of toxicity
  • Challenges and obstacles with multi-organ chips from a user’s perspective
     
  • 15:20 Afternoon Tea

    15:50 Validation of organ-on-a-chip systems for early toxicological assessments

    Lena Brucker

    Lena Brucker, Postdoctoral Scientist, Merck Healthcare KGaA
    View Bio

  • Strategic implementation of OOCs to reduce animal use and improve patient safety
  • Comparison of complex in vitro models and 2D Cell Cultures
  • Overcoming current challenges with regulatory understanding of complex in-vitro models
  • Strengthening future prospects of OOC technologies

     

  • 16:30 Applications of MPS in reproductive toxicology assessments

    Patrick Devine

    Patrick Devine, Scientific Director, Bristol Myers Squibb
    View Bio

  • Current outlook for MPS models of reproductive biology
  • Identifying and working to overcome the challenges for toxicology assessments
  • Future considerations for optimised research and analysi
  • 17:10 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Elad Katz

    Elad Katz

    Lead, Navigate Precision Biology, University of Dundee
    Lewis Chaytor

    Lewis Chaytor

    Senior Scientist, Astrazeneca
    Linda Lieberman

    Linda Lieberman

    Head of Host Pathogen Discovery Research, Merck & Co
    Masato Ohbuchi

    Masato Ohbuchi

    Senior Researcher, Astellas Pharma Inc.
    Philip Hewitt

    Philip Hewitt

    Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
    Scott MacDonnell

    Scott MacDonnell

    Director New Target Interrogation Group, Regeneron Pharmaceuticals
    Stefan Przyborski

    Stefan Przyborski

    Professor, Durham University
    Stephen Fowler

    Stephen Fowler

    Clinical Pharmacologist, Roche Pharmaceuticals

    Elad Katz

    Lead, Navigate Precision Biology, University of Dundee
    Elad Katz


    Dr Elad Katz has initiated the Navigate Precision Biology project in 2019 and led the generation of NaviPlate as well as its applications in oncology. He holds a BSc in Chemistry and a PhD in Immunology and participated in several business accelerator programmes and spin off projects. Dr Katz has been involved in many complex biology projects over the past 20 years and is focused on the inclusion of patient-derived materials in drug discovery.
     

    Etienne De Braekeleer

    Senior Research Scientist, Astrazeneca
    Etienne De Braekeleer

    Ilona Wehl

    PostDoc, Boehringer Ingelheim Pharma GmbH & Co. KG
    Ilona Wehl

    Dr. Ilona Wehl is a Postdoctoral Researcher in Investigative Toxicology within the Nonclinical Drug Safety Department at Boehringer Ingelheim Pharma GmbH & Co. KG in Biberach, Germany. She is a chemical biologist by training and received her PhD from the Karlsruhe Institute of Technology, Germany. During her career, she specialized in advanced cellular models as an alternative to animal models for the investigation of drug candidates. A major focus of her postdoctoral work is human multi-organ microphysiological systems (MPS) in combination with high-content imaging to elucidate complex mechanisms of toxicity and to improve pre-clinical decisions.

    Jessica Klein

    Scientist, Contractor, Genentech
    Jessica Klein

    Dr. Klein is a Scientist in Complex in vitro Systems at Genentech with expertise in 3D tissue culture models of gastrointestinal disease and toxicity. She did her postdoctoral training at Stanford University developing gastric organoid infection models to study interactions with an oncogenic bacterium that chronically colonizes the human stomach. After receiving a BS in Microbiology at the University of Washington, she worked as a researcher in nanoparticle toxicology at Pacific Northwest National Laboratories. She completed her PhD in Immunology and Infectious Diseases at Washington State University studying intracellular intestinal infection dynamics of Salmonella Typhimurium.

    Lena Brucker

    Postdoctoral Scientist, Merck Healthcare KGaA
    Lena Brucker

    I studied biology at the university of Mainz, finishing my studies with a Master’s degree in 2017. In 2018, I started my PhD in the lab of Helen May-Simera where I focused on the cellular mechanisms underlying genetic disorders called ciliopathies. After finishing my PhD in 2022, in started a Postdoc at Merck Healthcare KGaA in Darmstadt on Advanced Liver Cell Models. It is a joined project between DMPK and in vitro toxicology where I aim to establish 3D liver models that provide a more robust and reliable basis to study drug metabolism and toxicology, improving patient safety and reducing the need of animal models.

    Lewis Chaytor

    Senior Scientist, Astrazeneca
    Lewis Chaytor

    Lewis completed his CRUK funded PhD studentship at the Newcastle Cancer centre which focused on prostate cancer. During this time he generated ex vivo and organoid models of prostate cancer from primary tissue.
    In 2018 Lewis moved to the Stem Cell Institute in Cambridge where he worked to understand the role of master transcription factors in neuroblastoma differentiation.
    In 2021, he then moved to AstraZeneca and took a role as a Senior Scientist in the Cell Biology and Immunology team. His work now focusses on modelling drug resistance using CRISPR/cas9 and development of complex models of disease.
     

    Linda Lieberman

    Head of Host Pathogen Discovery Research, Merck & Co
    Linda Lieberman


    Dr. Lieberman is the Head of Host Pathogen Researck at Merck’s Exploratory Science Center and has been with Merck for 6 years. Her work focuses on understanding mucosal biology in the context of inflammation and infection. To this end, her group utilizes physiologically relevant primary in vitro cultures to model the epithelial barrier. The focus has been on understanding gut and lung biology. Linda received her Ph.D. in Immunology from the University of Pennsylvania.
     

    Luca Frenguelli

    Director of Biomaterials, Engitix Therapeutics
    Luca Frenguelli

    Manjunath Hedge

    Scientific Investigator & Associate Fellow, GlaxoSmithKline
    Manjunath Hedge

    Martina Pigoni

    Scientist, Roche Innovation Center
    Martina Pigoni

    Masato Ohbuchi

    Senior Researcher, Astellas Pharma Inc.
    Masato Ohbuchi

    Dr. Masato Ohbuchi, senior researcher in Astellas Pharma Inc. He has been working in pharmaceutical company over 10 years, and has expertise in the field of drug discovery research using human tissue/disease models such as organ-on-a-chip (OoC) and bioprinted tissue. He also has a lot of experience of collaborative research with OoC developers to utilize these cutting-edge technologies for drug discovery. Masato holds a masters degree and Ph.D. in drug metabolism and molecular toxicology from Tohoku Univ.

    Patrick Devine

    Scientific Director, Bristol Myers Squibb
    Patrick Devine

    Patrick J “PJ” Devine
    Current Position: Scientific Director in Discovery Toxicology in the department of Pharmaceutical Candidate Optimization at Bristol Myers Squibb in Cambridge MA, USA 02142
    Education: B.Sc. in Chemistry and Biology, University of Delaware (1992). Ph.D. in Toxicology, University of Maryland, Baltimore (1999).
    Summary/research interests: PJ Devine got his BSc in Biology/Chemistry at the U. of Delaware then a PhD in toxicology at the U. of Maryland, Baltimore. He studied reproductive toxicology as a post-doctoral fellow (U. of Arizona) and as a professor (INRS, Laval, QC), evaluating mechanism(s) of ovarian toxicity and fertility biomarkers. PJ worked in Preclinical Safety at Novartis from 2010-2022 and has recently joined Discovery Toxicology at Bristol Myers Squibb, where he advises oncology drug discovery teams on safety and is involved in investigative toxicology studies. He has leveraged simple and complex in vitro models, as well in vivo models, examining mechanisms of toxicity observed in preclinical or clinical studies. PJ is also involved in cross-industry consortia involving biomarkers (PSTC) and microphysiological systems (IQ MPS).
     

    Patrick Devine

    Scientific Director, Bristol Myers Squibb
    Patrick Devine

    Pelin Candarlioglu

    Cell Biologist/Bioengineer - Complex in Vitro Models, GlaxoSmithKline
    Pelin Candarlioglu

    Pelin Candarlioglu

    Bioengineer/Cell Biologist, GlaxoSmithKline
    Pelin Candarlioglu

    Philip Hewitt

    Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
    Philip Hewitt

    Rhiannon David

    Director, Microphysiological Systems, AstraZeneca
    Rhiannon David

    Dr Rhiannon David is Director of Microphysiological Systems (MPS) in Clinical Pharmacology and Safety Sciences at AstraZeneca, Cambridge, UK. Rhiannon leads the development and integration of advanced cell models, including spheroids and MPS, to improve the human-translation of pre-clinical safety assessment. Prior to joining AZ, following completion of her PhD at the University of Birmingham, Rhiannon undertook postdoctoral research at Imperial College London where she developed an interest in novel techniques that would improve the in vivo relevance of in vitro assays. After joining AZ in 2015, Rhiannon led the development of a bone marrow MPS for improved pre-clinical safety assessment. Rhiannon is now Director of MPS in Safety Innovation and leads the development and integration of advanced cell models, including spheroids and MPS, to improve the human-translation of pre-clinical safety assessment.

    Rhiannon David

    Director, Microphysiological Systems, AstraZeneca
    Rhiannon David

    Scott MacDonnell

    Director New Target Interrogation Group, Regeneron Pharmaceuticals
    Scott MacDonnell

    Dr. Scott MacDonnell obtained his undergraduate and master’s degrees in physiology from the University of Delaware and completed his doctoral work in cardiovascular physiology at Temple University in Philadelphia, PA. He completed a post-doctoral fellowship at Temple University Medical School in the lab of Dr. Steve Houser. His fellowship research focused on identifying mechanisms responsible for the pathogenesis of heart failure. Scott worked for 8-years as a principal scientist at Boehringer Ingelheim within the department of CardioMetabolic Disease Research where his research focused on identifying novel therapeutic treatment options for chronic kidney disease, heart failure, and fibrosis. Scott currently works at Regeneron Pharmaceuticals leading the newly formed New Target Interrogation team (NTI). NTI brings together teams from the Regeneron Genetics Center and Therapeutic areas to deliver multidisciplinary work through close collaborations, leveraging the best cross-functional expertise to rapidly investigate new potential drug targets validated by human genetics and aligned to meet unmet clinical needs.

    Stefan Przyborski

    Professor, Durham University
    Stefan Przyborski

    Stefan holds an academic position as Professor in Cell Technology at Durham University. He has 30 years’ experience in cell biology with specific interests in cell culture technology and tissue engineering research. In recent years he has developed a multi-disciplinary approach to the bioengineering of human tissue equivalents in vitro based on the fundamental principles of anatomy and physiology. He was the founder and CSO of Reinnervate, a biotechnology company he subsequently sold as a spinout from Durham University UK to Reprocell Europe and is their current CSO. Stefan is developing new and innovative ways to manage the growth and function of cultured cells and tissues. These enabling technologies have multiple applications and will be particularly relevant to bioengineering models of human tissues to advance basic research, drug discovery and reducing the use of animals in research. Notably significant advances have been made in skin and intestinal models aiding the development of consumer products and enabling the study of cellular mechanisms in healthy and diseased tissues.

    Stefan Przyborski

    Professor, Durham University
    Stefan Przyborski

    Stephen Fowler

    Clinical Pharmacologist, Roche Pharmaceuticals
    Stephen Fowler

    Stephen Fowler trained as a chemist at the University of Oxford (UK) before studying drug-metabolising enzyme structure-function relationships in his PhD at the University of Dundee (UK). Stephen has worked over the last 20 years in ADME scientist, senior scientist and group leader roles at AstraZeneca, Novartis and Roche and more recently as a clinical pharmacologist. His research interests are centered on enzymology, especially the contribution of UGTs to drug metabolism, and the use of new cellular systems to answer ADME questions.
    Working with colleagues across the pharmaceutical industry Stephen co-wrote the 2020 IQ consortium review “Microphysiological Systems for ADME Related Applications: Current Status and Recommendations for System Development and Characterization”. Some of the ‘next steps’ outlined in this review have recently been explored further using liver-chip and gut liver MPS, resulting in two further Lab on a Chip publications in 2022. The presentation will aim to cover practical examples of successes and challenges from recent validation activities.

    Relevant recent publications:
    Application of a Gut-Liver-on-a-Chip Device and Mechanistic Modelling to the Quantitative in vitro Pharmacokinetic Study of Mycophenolate Mofetil
    Lab on a Chip, 2022, 22, 2853–2868

    Exploration and Application of a Liver-on-a-Chip Device in Combination with Modelling and Simulation for Quantitative Drug Metabolism Studies
    Lab on a Chip, 2022, 22, 1187-1205

    Microphysiological Systems for ADME Related Applications: Current Status and Recommendations for System Development and Characterization
    Lab Chip 2020,20, 446-467

    Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools
    SLAS Discovery 2019, Vol. 24(5) 523–536
     

    Sponsors

    Exhibitors

    Supporters

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Speaker Biographies

    Download

    Co-chair Invitation Letter

    Download

    Conference Brochure

    Download

    Past Attendees List

    Download

    Sponsors


    CelVivo

    Sponsors
    https://celvivo.com/

    CelVivo provide a 3D Cell Culture technology mimicking in vivo performance.

    The CelVivo system creates an environment which promotes the growth and maintenance of large 3D tissue mimetic structures, whether they are spheroids, organoids, acini and other aggregates.

    Our ambition is to provide cells with conditions which allow them to develop functionality which closely mimics that seen in the intact organism. To achieve this, we have developed a system which obviates the need for scaffolds, gels or any type of additives which might perturb gene expression away from its natural baseline equilibrium. Furthermore, we have very significantly reduced contact with plastics and reduced shear forces.



    Systemic Bio

    Sponsors
    https://systemic.bio/

    Systemic Bio is a 3D Systems company based in Houston, Texas, focused on the development of vascularized organ models made out of hydrogels and human cells to be used for drug discovery and development. This novel organ-on-a-chip platform, h-VIOS (human vascularized integrated organ systems), offers unprecedented ability to create complex microphysiological systems.


    Exhibitors


    Promega

    Exhibitors
    http://www.promega.com

    Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 4,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification.

    Promega products are used by scientists asking fundamental questions about biological processes and applying scientific knowledge to diagnose and treat diseases, discover new therapeutics and for use in genetics and DNA testing.

    Founded in 1978, the company is headquartered in Madison, USA, with branches in 16 countries including Southampton UK and over 50 global distributors.


    Media Partners


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Genetic Engineering News

    Supporters
    http://www.genengnews.com

    Genetic Engineering & Biotechnology News (GEN) is the most authoritative and widely read biotechnology news publication in the world.Published 21 times a year,GEN's unique news and technology focus include the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drugs and biomarker discovery, bioprocessing, clinical research, molecular diagnostics and biobusiness. For a free subscription go to: http://www.genengnews.com/subscriptions.aspx


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    3DMedNet

    Supporters
    https://www.3dmednet.com/

    3DMedNet is an online community providing the latest news, opinions and peer-reviewed journal articles focused on the applications of 3D printing technologies in medicine, including 3D-printed medical devices, surgery, pharmaceuticals, bioprinting, dentistry and the regulatory landscape. Visit 3DMedNet today at: www.3dmednet.com


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out